Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This analysis of localized appendiceal adenocarcinoma reveals low relapse rates post-resection, identifies key histopathologic and molecular relapse predictors, and finds no significant benefit from adjuvant chemotherapy, challenging conven
A retrospective study delineates relapse risks and survival outcomes in adult acute myeloid leukemia patients who achieve first complete remission without undergoing allogeneic stem cell transplantation, highlighting venetoclax’s role in re
Low-level FLT3-ITD microclones, detected via NGS in young adults with AML, independently increase relapse risk comparable to macroclones, challenging current risk stratification and underscoring the need to integrate advanced genetic testin
Post-cycle 2 CBFB::MYH11 MRD best predicted outcomes in favorable-risk AML. Patients with levels ≥1% had higher relapse risk, and those receiving allo-HCT in CR1 had better 3-year disease-free survival than chemotherapy consolidation.
In adults with MOGAD, stopping maintenance therapy was associated with a low 1-year relapse risk, especially after longer treatment and a longer relapse-free interval. The findings support individualized decisions and close follow-up after
The HAMLETT trial demonstrates that early dose reduction after first-episode psychosis increases short-term relapse risk but correlates with superior functional outcomes at three to four years, suggesting a potential ‘learning effect&
A large French registry study shows that how disease-modifying therapies (DMTs) are managed during pregnancy meaningfully affects relapse rates in relapsing‑onset MS; prolonged natalizumab interruption and fingolimod use carry the highest r
This review synthesizes evidence from a large randomized trial comparing early antipsychotic dose reduction/discontinuation versus maintenance after first-episode psychosis remission, emphasizing short-term risks and long-term functional ga
Managing disease-modifying therapies (DMTs) during pregnancy in women with multiple sclerosis significantly affects relapse risk, with anti-CD20 strategies demonstrating superior protection compared to other approaches.